The DOI matches its Crossref record; the references it cites are not checked yet.
GIP: An Inconsequential Incretin or Not?
Open accessAbstract
The “incretin effect” refers to the enhancement of insulin secretion in response to an oral glucose load relative to that of an isoglycemic intravenous glucose challenge (1). In humans, the incretin effect is mediated by two peptide hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are secreted from enteroendocrine cells in response to nutrients entering the gut. GLP-1 secretion from L-cells, found in highest density in the distal ileum but also throughout the small and large intestine, is stimulated by glucose, amino acids, and fat. GIP, in contrast, is produced by the K-cells in the proximal duodenum; its secretion is also stimulated by glucose, but is particularly enhanced by fat (2). Both GLP-1 and GIP are derived from prohormones (proglucagon and pro-GIP, respectively) and secreted as active hormones. The effects of both GLP-1 and GIP are mediated by specific G protein–coupled receptors present on the plasma membrane of β-cells and other target tissues. GLP-1 and GIP increase insulin secretion from β-cells in a glucose-dependent manner. In rodents, GLP-1 and GIP also enhance β-cell mass by increasing rates of proliferation and decreasing rates of apoptosis. Many physiological effects of GLP-1 and GIP do not overlap, however. GLP-1 suppresses glucagon secretion, slows gastric emptying, and has central nervous system effects to regulate appetite, whereas GIP does not. GIP, on the other hand, has direct effects on adipocytes to promote triglyceride storage (1). The incretin system, therefore, facilitates integrated physiological responses to meals of different size and composition allowing ingested nutrients to be optimally metabolized. The incretin effect is an important determinant of glucose tolerance. In patients with type 2 diabetes, the incretin effect …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It has been established that hyperglycaemia induces down-regulation of GIPR expression in beta-cells, so it is plausible that in this study GIPR expression may have been upregulated in these cells due to reducing plasma glucose levels.159”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [159]
In the citing paper
“Hence, the diminished incretin effect is due to dysfunctional beta-cells.159”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [159]
In the citing paper
“It has been established that hyperglycaemia induces down-regulation of GIPR expression in beta-cells, so it is plausible that in this study GIPR expression may have been upregulated in these cells due to reducing plasma glucose levels.159”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 12 · Cited by 19
Metadata
- Authors
- Pratley, R. E.
- Affiliations
- University of Vermont (US)
- Corresponding author
- Pratley, Richard E.
- ORCID
- Pratley, Richard E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-07-01
- Volume
- 33
- Issue
- 7
- Pages
- 1691-1692
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2890383
- OpenAlex
- W2145489764
- Cited by
- 19
- References
- 12
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2017: 1 · 2016: 1 · 2012: 1
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucose-dependent insulinotropic polypeptide, incretin effect, glucagon-like peptide-1, insulin secretion, enteroendocrine cells, beta-cell proliferation, type 2 diabetes, glucose tolerance, glucagon suppression, gastric emptying, appetite regulation
- MeSH terms
- Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Glucose Intolerance, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GIP: An Inconsequential Incretin or Not? https://app.cochat.ai/papers/10.2337/dc10-0704
- The paper
- Pratley, R. E. (2010). GIP: An Inconsequential Incretin or Not? Diabetes Care. https://doi.org/10.2337/dc10-0704
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.